Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion

Prostaglandins & Other Lipid Mediators
Philippe KolhJean-Michel Dogné

Abstract

To investigate whether BM-573 (N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea), an original combined thromboxane A2 synthase inhibitor and receptor antagonist, prevents reperfusion injury in acutely ischemic pigs. Twelve animals were randomly divided in two groups: a control group (n = 6) intravenously infused with vehicle, and a BM-573-treated group (n = 6) infused with BM-573 (10 mg kg(-1) h(-1)). In both groups, the left anterior descending (LAD) coronary artery was occluded for 60 min and reperfused for 240 min. Either vehicle or BM-573 was infused 30 min before LAD occlusion and throughout the experiment. Platelet aggregation induced by arachidonic acid ex vivo measured was prevented by BM-573. In both groups, LAD occlusion decreased cardiac output, ejection fraction, slope of stroke work--end-diastolic volume relationship, and induced end-systolic pressure-volume relationship (ESPVR) rightward shift, while left ventricular afterload increased. Ventriculo-arterial coupling and mechanical efficiency decreased. In both groups, reperfusion further decreased cardiac output and ejection fraction, while ESPVR displayed a further rightward shift. Ventriculo-arterial coupling and mechanical efficiency remai...Continue Reading

References

May 1, 1975·Journal of Molecular and Cellular Cardiology·D J HearseD Border
Jan 1, 1987·Journal of Cardiovascular Pharmacology·M E BrezinskiA M Lefer
Apr 1, 1986·British Journal of Pharmacology·K Schrör, C Thiemermann
Mar 1, 1988·Journal of Molecular and Cellular Cardiology·M TadaM Nishida
Jul 1, 1988·Progress in Cardiovascular Diseases·W SchaperJ Schaper
Oct 16, 1986·The New England Journal of Medicine·D J FitzgeraldG A FitzGerald
Jan 1, 1984·Journal of Molecular and Cellular Cardiology·I M TaylorE Downar
Nov 1, 1981·Journal of Pharmacological Methods·D C WarltierH L Brooks
Jul 1, 1994·Journal of Molecular and Cellular Cardiology·N BowlingD E Mais
Sep 2, 1993·The New England Journal of Medicine·UNKNOWN GUSTO investigators
Mar 11, 1993·The New England Journal of Medicine·F ZijlstraH Suryapranata
May 18, 1999·Cardiovascular Research·B LambermontV D'Orio
Feb 27, 2003·Journal of Cardiovascular Pharmacology·Zhi-Dong GeGarrett J Gross

❮ Previous
Next ❯

Citations

Feb 2, 2010·Nature Reviews. Drug Discovery·Alan D Michelson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.